DiscGenics announced it has raised $50 million in Series C funding led by Ci:z Investment LLP with participation from new investors including Eagle Fund SP1 LLP, Medical Incubator Japan and CareNet of Japan. This round of funding brings the company to just over $71 million to-date.
Discgenics will use the capital to support ongoing clinical trials of its injectable Discogenic Cell Therapy (IDCT) for lumbar degenerative disc disease, fund future commercialization efforts in the U.S. and Japan as well as scale its allogeneic cell manufacturing facility in Salt Lake City, Utah.
DiscGenics announced it has raised $50 million in Series C funding led by Ci:z Investment LLP with participation from new investors including Eagle Fund SP1 LLP, Medical Incubator Japan and CareNet of Japan. This round of funding brings the company to just over $71 million to-date.
Discgenics will use the capital to support ongoing...
DiscGenics announced it has raised $50 million in Series C funding led by Ci:z Investment LLP with participation from new investors including Eagle Fund SP1 LLP, Medical Incubator Japan and CareNet of Japan. This round of funding brings the company to just over $71 million to-date.
Discgenics will use the capital to support ongoing clinical trials of its injectable Discogenic Cell Therapy (IDCT) for lumbar degenerative disc disease, fund future commercialization efforts in the U.S. and Japan as well as scale its allogeneic cell manufacturing facility in Salt Lake City, Utah.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
